Overview


According to FutureWise analysis, the market for Dasatinib Drugs is expected to grow with a CAGR of 6.22% over the forecast period 2024-2032, and reach a market value of US$ 7.04 Billion by 2031. 

Dasatinib, a tyrosine kinase inhibitor (TKI), is prescribed for specific forms of leukemia, including Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). TKIs function by inhibiting enzymes called tyrosine kinases, crucial players in cell growth and division. By impeding these enzymes, dasatinib can effectively hinder the proliferation of cancer cells. Being a multi-targeted TKI, dasatinib can obstruct numerous tyrosine kinases. This quality renders it exceptionally potent against Ph+ CML and ALL, as it can address both the BCR-ABL tyrosine kinase, the culprit behind these cancers, and other tyrosine kinases potentially implicated in their genesis and progression. Administration of dasatinib entails once-daily oral intake, available in tablet and suspension forms. The prescribed dosage depends on the specific type of cancer being treated and the patient's unique characteristics.

Clinical trials have demonstrated dasatinib's remarkable efficacy against Ph+ CML and ALL, often resulting in high complete remission rates in afflicted patients. Common side effects include fatigue, vomiting, nausea, muscle cramps, rash, and headache. Vigilant monitoring of patients for potential side effects during dasatinib treatment is crucial. Treatment adjustments or discontinuation may be necessary for severe side effects.

FutureWise Market Research has published a report that provides an insightful analysis of Dasatinib Drugs Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Dasatinib Drugs Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Bristol-Myers Squibb (BMS)LUCIUS Pharma
  • MSN Labs
  • Hetero Labs
  • Alembic Pharma
  • JINLAN Pharm-Drugs Technology Co., Ltd.
  • Reddy's
  • Zhejiang Hisun Pharma

(Note: The list of the major players will be updated with the latest market scenario and trends)

Continuous research and clinical trials exploring new applications and formulations of dasatinib, such as monthly injectable versions and nanoparticle formulations, contribute to the evolution and expansion of the dasatinib market. Dasatinib has demonstrated high efficacy in the treatment of specific forms of leukemia, particularly Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) and hence drives the market. Its ability to target the BCR-ABL tyrosine kinase, a key driver of these cancers, positions it as a valuable therapeutic option. As a multi-targeted tyrosine kinase inhibitor (TKI), dasatinib can block several tyrosine kinases in cell signalling pathways. This makes it particularly effective against cancers with complex genetic profiles, allowing it to address multiple targets simultaneously and hence propels the market. In addition, government initiatives are being taken for raising awareness and this bolsters the market growth.

However, there are significant restraints for this market. Dasatinib and related healthcare expenses may burden some patients, particularly in regions with limited access to healthcare resources or those without adequate insurance coverage. Dasatinib can lead to various side effects, including fatigue, gastrointestinal issues, skin rash, and more severe effects like myelosuppression, fluid retention, and cardiovascular complications. These side effects can impact patient compliance and treatment decisions.  Dasatinib and related healthcare expenses may burden some patients, particularly in regions with limited access to healthcare resources or those without adequate insurance coverage and restraints the market growth.

By Demographic

  • Age
  • Gender
  • Income

By Behaviour 

  • PrescriptionPatterns
  • Treatment History
  • Compliance

By Psychographic

  • Lifestyle
  • Attitudes and Beliefs
  • Awareness

By Region

  • Europe
  • North America
  • Asia Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due to the high prevalence of CML and ALL in the region, as well as the increasing adoption of dasatinib as a first-line therapy for these conditions, robust healthcare infrastructure, the prominent presence of key industry players, a surge in chronic disease cases, and heightened research endeavors in this geographical region.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Dasatinib Drugs Market By Demographic, By Behaviour, By Psychographic, and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction

    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology

    •   1. Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2. Primary Data
              1.2.1. Key Data from Primary Sources
        3. Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary

    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Dasatinib Drugs Market Variables, Trends & Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview

    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Dasatinib Drugs Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Dasatinib Drugs Market Analysis Tools

    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Dasatinib Drugs Market, By Demographic Historical Analysis and Forecast 2024-2032 (USD Million)
      1. Age
      2. Gender
      3. Income
  • 8.  Dasatinib Drugs Market, By Behaviour Historical Analysis and Forecast 2024-2032 (USD Million)
      1. PrescriptionPatterns
      2. Treatment History
      3. Compliance
  • 9.  Dasatinib Drugs Market, By Psychographic Historical Analysis and Forecast 2024-2032 (USD Million)
      1. Lifestyle
      2. Attitudes and Beliefs
      3. Awareness
  • 10.  North America Dasatinib Drugs Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 11.  Latin America Dasatinib Drugs Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 12.  Europe Dasatinib Drugs Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 13.  Asia Pacific Dasatinib Drugs Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032  

  • 14.  Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 15.  Market Share Analysis and Competitive Landscape

    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 16.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. Bristol-Myers Squibb (BMS)LUCIUS Pharma
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. MSN Labs
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. Hetero Labs
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. Alembic Pharma
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. JINLAN Pharm-Drugs Technology Co., Ltd.
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. Reddy's
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview
        7. Zhejiang Hisun Pharma
           7.1. Company Overview
           7.2. Product Portfolio
           7.3. SWOT Analysis
           7.4. Financial Overview
           7.5. Strategic Overview

  • 17.  Pre and Post COVID-19 Impact

    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated
      by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.  FutureWise SME Key Takeaway Points for Client

    •   


Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11